Literature DB >> 11228376

Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease.

G A Prince1, F Denamur, M Deschamps, N Garçon, J P Prieels, M Slaoui, C Thiriart, D D Porter.   

Abstract

The mechanisms by which administration of a formalin-inactivated respiratory syncytial virus vaccine resulted in enhanced disease among children after they later became naturally infected with the virus remains largely undefined. After immunization and live virus challenge, the cotton rat demonstrated the histopathologic marker of the enhanced disease, polymorphonuclear leukocyte infiltration of lung alveolar spaces. We now report that immunization with formalin-inactivated vaccine formulated with the adjuvant, 3-deacylated monophosphoryl lipid A, dramatically reduces or eliminates the polymorphonuclear leukocyte infiltration within the alveoli of cotton rats post-challenge. We suggest, that this or similar adjuvants may be beneficial components of candidate non-replicating respiratory syncytial virus vaccines, whose development has been hampered by safety concerns.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228376     DOI: 10.1016/s0264-410x(00)00417-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

2.  Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo.

Authors:  G A Prince; M G Ottolini; A Moscona
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective.

Authors:  Nico Marr; Stuart E Turvey; Nathalie Grandvaux
Journal:  Trends Microbiol       Date:  2013-10-09       Impact factor: 17.079

4.  Novel drugs targeting Toll-like receptors for antiviral therapy.

Authors:  Mira C Patel; Kari Ann Shirey; Lioubov M Pletneva; Marina S Boukhvalova; Alfredo Garzino-Demo; Stefanie N Vogel; Jorge Cg Blanco
Journal:  Future Virol       Date:  2014-09       Impact factor: 1.831

5.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

6.  A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Stefanie N Vogel
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

7.  Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice.

Authors:  Keyan Chen; Kui Zhao; Wenqi He; Wei Gao; Chuanbo Zhao; Li Wang; Wei Pan; Deguang Song; Chengli Wang; Feng Gao
Journal:  Clin Vaccine Immunol       Date:  2012-04-18

8.  Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.

Authors:  Jong Seok Lee; Min Kyoung Cho; Hye Suk Hwang; Eun-Ju Ko; Yu-Na Lee; Young-Man Kwon; Min-Chul Kim; Ki-Hye Kim; Young-Tae Lee; Yu-Jin Jung; Sang-Moo Kang
Journal:  J Interferon Cytokine Res       Date:  2014-07-22       Impact factor: 2.607

9.  The cotton rat model of respiratory viral infections.

Authors:  Marina S Boukhvalova; Gregory A Prince; Jorge C G Blanco
Journal:  Biologicals       Date:  2009-04-25       Impact factor: 1.856

Review 10.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.